Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 445

1.

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C.

BMC Genomics. 2008 May 22;9:239. doi: 10.1186/1471-2164-9-239.

2.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
3.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

4.

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.

Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer. 2006;13(1):74-83.

5.

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.

Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.

Clin Cancer Res. 2007 Apr 1;13(7):2061-7.

6.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

7.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID:
17636399
8.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

9.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
10.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
11.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.

Ann Oncol. 2006 May;17(5):818-26. Epub 2006 Feb 23.

12.

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

Kok M, Koornstra RH, Mook S, Hauptmann M, Fles R, Jansen MP, Berns EM, Linn SC, Van 't Veer LJ.

Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun 26.

PMID:
22738860
13.
14.

The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.

Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, Shioda T, Ma XJ, Sgroi DC.

Clin Cancer Res. 2007 Nov 1;13(21):6327-34.

15.

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

Kok M, Koornstra RH, Margarido TC, Fles R, Armstrong NJ, Linn SC, Van't Veer LJ, Weigelt B.

J Pathol. 2009 Jul;218(3):316-26. doi: 10.1002/path.2544.

PMID:
19353633
16.

Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.

Nesković-Konstantinović ZB, Nikolić-Vukosavljević DB, Branković-Magić MV, Mitrovic LB, Spuzić I.

Neoplasma. 2000;47(2):107-13.

PMID:
10985476
17.

[Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].

Chanrion M, Darbon JM.

Bull Cancer. 2008 May;95(5):513-8. doi: 10.1684/bdc.2008.0646. Review. French.

PMID:
18541515
18.

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM.

J Clin Oncol. 2006 Apr 10;24(11):1656-64. Epub 2006 Feb 27.

19.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

20.

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.

Kerr DA 2nd, Wittliff JL.

Horm Cancer. 2011 Oct;2(5):261-71. doi: 10.1007/s12672-011-0080-8.

PMID:
21826535
Items per page

Supplemental Content

Write to the Help Desk